Two Phase III studies are currently ongoing to evaluate anti–PD-L1 antibodies combined with bevacizumab in patients with HCC at high risk of tumor recurrence following potentially curative liver resection or tumor ablation (220, 221). This evidence concerns the gene CD274 and neoplasm.